Avid Radiopharmaceuticals
David Wilson began their work experience as a Research Chemist at Great Lakes Chemicals in 1994. David then worked as a Senior Production Manager at Girindus America from 2001 to 2013. After that, they transitioned to Nitto Denko Avecia Inc., where they held the position of Small Molecules Manager from 2013 to 2017. Currently, they are the Senior Director of Contract Manufacturing at Avid Radiopharmaceuticals, starting in 2017.
David Wilson obtained their Bachelor of Science and Bachelor of Arts degrees in Chemistry and German from the University of Illinois Urbana-Champaign, during the period from 1979 to 1986. David then pursued their education further, earning a Ph.D. in Physical Organic Chemistry from the University of Wisconsin-Madison, between 1986 and 1994.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.